SGAM
CYTK icon

Smith Group Asset Management’s Cytokinetics CYTK Stock Holding History

Smith Group Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-155,670
Closed -$1.63M – 479
2015
Q4 		$1.63M Sell
155,670
-21,340
-12% -$209K 0.05% 154
2015
Q3 		$1.18M Buy
177,010
+170,570
+2,649% +$1.16M 0.05% 159
2015
Q2 		$43K Buy
6,440
+550
+9% +$3.61K ﹤0.01% 283
2015
Q1 		$40K Buy
5,890
+770
+15% +$5.75K ﹤0.01% 337
2014
Q4 		$41K Hold
5,120
– – ﹤0.01% 318
2014
Q3 		$18K Hold
5,120
– – ﹤0.01% 308
2014
Q2 		$24K Sell
5,120
-205,338
-98% -$1.25M ﹤0.01% 301
2014
Q1 		$2M Sell
210,458
-2,211
-1% -$20K 0.08% 160
2013
Q4 		$1.38M Buy
212,669
+71,547
+51% +$470K 0.05% 169
2013
Q3 		$1.07M Buy
+141,122
New +$1.51M 0.04% 177

Other funds holding CYTK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Smith Group Asset Management's CYTK Position: Q1 2016 in Review

Smith Group Asset Management sold out of Cytokinetics (CYTK) in Q1 2016, closing a stake of 155,670 shares — an estimated $1.63M sold.

Smith Group Asset Management first reported a position in CYTK in Q3 2013 and held it in 10 quarters. The position peaked at $2M in Q1 2014. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2016.

  • Smith Group Asset Management reported no remaining Cytokinetics position as of Q1 2016 after selling out during the quarter.
  • Smith Group Asset Management sold 155,670 Cytokinetics shares in Q1 2016, an estimated $1.63M.
  • Smith Group Asset Management first reported a position in Cytokinetics in Q3 2013 and held it in 10 quarters.
  • Smith Group Asset Management's Cytokinetics position peaked at $2M in Q1 2014.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2016.

Based on Smith Group Asset Management's 13F filing for Q1 2016, filed 3 May 2016.